How to Help Cancer Research
Get Involved
Help us get one step closer to a cure. There are so many ways to lend a hand and improve the lives of patients and families impacted by ovarian and all gynecologic cancers.
How to Help Cancer Research
Get Involved
Help us get one step closer to a cure. There are so many ways to lend a hand and improve the lives of patients and families impacted by ovarian and all gynecologic cancers.
Our Numbers
OCRA is the world’s leading organization fighting ovarian and all gynecologic cancers on every front while supporting patients and their families and advocating on their behalf.
- Invested in research
- $140M
- In Federal Research and Education Funding
- $3.8B
- People supported each year
- 140K
Ways to Give
Join us as we drive innovation, offer hope, and invest in groundbreaking research that saves lives. Your generous support will allow us to continue to fund innovative research in our search for a cure, provide compassionate support to patients and their families, and advocate for everyone affected by ovarian and all gynecologic cancers.
Honor a Loved One
Partnership Opportunities
Sponsor a Scientist
Workplace Giving
Estate Planning
Volunteer & Engage
Whether advocating on Capitol Hill, being there for someone who is newly diagnosed, or helping educate the medical professionals of tomorrow about ovarian cancers, learn how your involvement can make a difference.
Fundraise
OCRA Heroes across the country are making a difference in the fight against ovarian and all gynecologic cancers by raising awareness and critical funds for OCRA’s research, advocacy, and patient support programs. Become an OCRA Hero and turn your passion into purpose.
Start a Fundraiser
Find a Fundraiser
Related Topics
OCRA President & CEO Audra Moran Named Crain’s 2026 Notable Leader in Health Care
Audra Moran, President and CEO of Ovarian Cancer Research Alliance (OCRA), has been recognized as a Crain’s New York Business 2026 Notable Leader in Health Care. Crain’s annual recognition spotlights health care executives whose leadership, innovation, and community commitment set a high bar for the field. Honorees are selected based on demonstrated impact, both within … Continued
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued